STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Medically reviewed by Danielle Weiss, MD Diabetic macular edema (DME) is a leading cause of vision loss in people with ...

The rise of GLP-1s, which were initially approved for diabetes management and later for obesity treatment, underscores this ...

Marci Wright, certified diabetes educator at UT Health Tyler, said people who ages 35 and older should be screened for diabetes.

Policymakers should focus on both obesity prevention and better access to treatment for those already living with obesity.

I often discuss the importance of blood sugar management. Healthcare providers routinely test blood sugar levels because high ...